



Letter 04

From: Anna Irwin MD <irwina@slhs.org>

Sent: Tuesday, April 28, 2020 3:30 PM

To: Eide, Tamara J. <Tamara.Eide@dhw.idaho.gov>

Subject: Medicaid Ajovy [External Email]

Dear Tammy,

My name is Dr. Anna Irwin. I am a neurologist for St. Luke's Boise and Meridian group. I see a lot of migraine patients and have decent experience with CGRP therapy.

It was brought to my attention that on May 15th Medicaid will be reviewing their CGRP policy...

I would like to voice my strong support for Ajovy therapy. In my experience it has been more beneficial when compared to Aimovig. In fact, I have switched a few patients from Aimovig to Ajovy and saw better results. I also see less side effects (no constipation on Ajovy, which I see in some patients on Aimovig). I have not used Emgality much, so I do not have strong clinical perspective on Ajovy vs Emgality.

I hope this unsolicited advice helps with your decision making process 😊

Best wishes,

Dr. Anna Irwin
208-381-7335